Beijing, China

Chenming Hu



 

Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Chenming Hu: Innovator in Pharmaceutical Compounds

Introduction

Chenming Hu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating various diseases. With a total of 4 patents, his work has garnered attention in the scientific community.

Latest Patents

Among his latest patents is the invention of an acylamino bridged heterocyclic compound. This compound, along with its pharmaceutically acceptable salts and derivatives, is designed for the treatment or prevention of autoimmune diseases, tumors, and neurodegenerative diseases related to receptor-interacting protein kinase-1 (RIPK1). Another notable patent involves urea-substituted aromatic ring-linked dioxinoquinoline compounds. This invention provides a preparation method for these compounds, which act as inhibitors of tyrosine kinases, thus offering potential treatments for disorders related to these enzymes.

Career Highlights

Chenming Hu has worked with Beijing Scitech-mq Pharmaceuticals Limited, where he has applied his expertise in pharmaceutical development. His innovative approaches have led to advancements in drug preparation and therapeutic applications.

Collaborations

Throughout his career, Chenming has collaborated with notable colleagues, including Qiang Zhang and Yansheng Liu. These partnerships have contributed to the success of his research and the development of his patented compounds.

Conclusion

Chenming Hu's contributions to pharmaceutical innovations highlight his role as a key inventor in the field. His patents reflect a commitment to addressing critical health challenges through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…